Document is current

Article History

Received: 6 September 2019

Accepted: 31 October 2019

First Online: 7 January 2020

Competing interests

: Dr Potkin has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Gerson Lehrman Group, Lundbeck, Medscape, Merck, Otsuka, Pfizer, Sunovion, Takeda, Teva, Toyama Chemical Co, and Vanda Pharmaceuticals and has received grant support from Allergan, Otsuka, Lundbeck, Takeda, the University of California San Diego, and the University of Southern California. Dr Kane has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medscape, Neurocrine, Newron, Otsuka, Pfizer, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva. He has received grant support from Janssen/J&J, Lundbeck, and Otsuka. He is a shareholder of The Vanguard Research Group and LB Pharma. Dr Correll has been a consultant and/or advisor or received honoraria from Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Rovi, Servier, Sunovion, Supernus, Takeda, and Teva. He reports providing expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka and serving on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Sumitomo Dainippon, Supernus, and Teva. He received royalties from UpToDate. He received grants from Janssen and Takeda and is a shareholder of LB Pharma. Dr Lindenmayer has been a consultant for Alkermes, Janssen/J&J, Lundbeck, Neurocrine, Newron, and Otsuka, and has received research grant support from Alkermes, Astellas, Avanir, Intracellular, Janssen, Neurocrine, Newron, Roche, and Takeda. Dr Agid has been a consultant and/or advisor to or has received honoraria from Janssen-Ortho (Johnson & Johnson), Otsuka, Lundbeck, Sumitomo Dainippon Pharma (DSP), Mylan Pharmaceuticals, and HLS Therapeutics. He has received grant support from Janssen-Ortho (Johnson & Johnson), Otsuka, Boehringer Ingelheim, and Neurocrine Biosciences. Dr Marder has been a consultant or advisory board member for Allergan, Boehringer Ingelheim, Lundbeck, Neurocrine, Newron, Otsuka, Roche, and Teva, and has received research support from Boehringer Ingelheim, Neurocrine, and Takeda. Dr Olfson has served as a consultant to Lundbeck. Dr Howes has received investigator-initiated research funding from and/or participated in advisory/speaker meetings organized by Angellini, Autifony (grants only), Biogen (non-financial support), Heptares (grants only), Janssen, Lundbeck, Otsuka, Sunovion, Rand (non-financial support), and Roche. Neither Dr Howes nor his family have been employed by or have holdings/a financial stake in any biomedical company.